NMDA receptor function in mouse models of Huntington disease

Journal of Neuroscience Research

Volumn 66, Issue 4, 2001, Pages 525-539

  Cepeda, Carlos ^a   Ariano, Marjorie A ^b   Calvert, Christopher R ^a   Flores Hernández, Jorge ^a   Chandler B, Scott H ^a   Leavitt, Blair R ^c   Hayden, Michael R ^c   Levine, Michael S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b The Chicago Medical College   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Calcium; Huntington disease; Medium spiny neuron; NMDA receptor; R6 2 transgenic; Striatum; Transgenic models; YAC transgenic

Indexed keywords

AMPA RECEPTOR; CALCIUM ION; HUNTINGTIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CONTROLLED STUDY; CORPUS STRIATUM; EXON; GENE CONTROL; GENE EXPRESSION; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; MEMBRANE CURRENT; MOUSE; NERVE CELL DEGENERATION; NERVE INJURY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; TRANSGENIC MOUSE;

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ANIMALS; BEHAVIOR, ANIMAL; CALCIUM CHANNELS; CALCIUM SIGNALING; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; HUNTINGTON DISEASE; IMMUNOHISTOCHEMISTRY; ION CHANNELS; MEMBRANE POTENTIALS; MICE; MICE, NEUROLOGIC MUTANTS; MICE, TRANSGENIC; MUTATION; N-METHYLASPARTATE; NEOSTRIATUM; NEURONS; ORGAN CULTURE TECHNIQUES; PATCH-CLAMP TECHNIQUES; RECEPTORS, N-METHYL-D-ASPARTATE; SYNAPTIC TRANSMISSION;

EID: 0035889535     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.1244     Document Type: Article

References (54)

1. + current in pyramidal neurons from rat sensorimotor cortex
2. + channels in Huntington disease transgenic mice
3. Striatal excitatory amino acid subunit expression in the D1A-dopamine receptor-deficient mouse
4. 2+ currents in acutely isolated, adult rat neostriatal neurons
5. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases?
6. Replication of the neurochemical characteristics of Huntington disease by quinolinic acid
7. Severe deficiencies in dopamine signaling in presymptomatic Huntington disease mice
8. Early effects of intrastriatal injections of quinolinic acid on microtubule-associated protein-2 and neuropeptides in rat basal ganglia
9. Developmental changes in the voltagedependence of neocortical NMDA responses
10. Characterization of progressive motor deficits in mice transgenic for the human Huntington disease mutation
11. Differential expression of AMPA receptor subunits in NOS-positive neurons of cortex, striatum, and hippocampus
12. Early and progressive electrophysiological alterations in the cortico-striatal pathway in a mouse model of Huntington disease
13. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene
14. Neuroanatomicalfeatures of a transgenic model of Huntington disease
15. 2+ block of NMDA-receptor channels as a mechanism of modulation
16. Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin
17. NMDA receptor-mediated currents and calcium responses in neostriatal medium spiny neurons from transgenic mice expressing mutant huntingtin
18. Glutamate neurotoxicity and diseases of the nervous efef system
19. An animal model for Huntington disease
20. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation
21. Excitotoxic injury of the neostriatum: A model for Huntington disease
22. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain
23. Neuroprotective effects of creatine in a transgenic mouse model of Huntington disease
24. Characterization and mechanism of glutamate neurotoxicity in primary striatal cultures
25. 2+ indicators with greatly improved fluorescence properties
26. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches
27. Transgenic mice expressing a Huntington disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity
28. A YAC mouse model for Huntington disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration
29. Effect of mutant huntingtin expression on neuronal glutamate receptor-mediated calcium increases
30. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington disease chromosomes
31. Electrophysiological and morphological changes in striatal neurons in asymptomatic and symptomatic R6/2 Huntington disease transgenic mice
32. Perforant path transections protect hippocampal granule cells from kainate lesion
33. Development and characterization of a novel transgenic model of Huntington disease, which recapitulates features of the human illness
34. Mutant huntingtin dependent cellular changes in the cortex predict behavioral and electrophysiological abnormalities
35. Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington disease
36. Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity
37. Selective discrimination learning impairments in mice expressing the human Huntington disease mutation
38. Decreased expression of striatal signaling genes in a mouse model of Huntington disease
39. Investigation of resistance to quinolinic acid lesion in the striatum of Huntington disease transgenic mice
40. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice
41. Kainate-induced degeneration of neostriatal neurons: Dependency upon corticostriatal tract
42. Decrease in striatal enkephalin mRNA in mouse models of Huntington disease
43. Mice transgenic for the human Huntington disease mutation have reduced sensitivity to kainic acid toxicity
44. Abnormal synaptic plasticity and impaired spacial cognition in mice transgenic for exon 1 of the human Huntington disease mutation
45. Behavioral abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA
46. Preferential loss of preproenkephalin vs. preprotachykinin neurons from the striatum of Huntington disease patients
47. Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease
48. Excitotoxic models for neurodegenerative disorders
49. Huntington disease: The challenge for cell biologists
50. Nonapoptotic neurodegeneration in a transgenic model of Huntington disease
51. The generalization of student's problem when several different population variances are involved
52. 2+
53. Mutant huntingtin enhances excitotoxic cell death